Mariano Provencio1, Ana Royuela2, María Torrente1, Marina Pollán3, José Gómez-Codina4, Pilar Sabín5, Marta Llanos6, Josep Gumá7, Cristina Quero8, Ana Blasco9, David Aguiar10, Francisco Ramón García-Arroyo11, Javier Lavernia12, Natividad Martínez13, Manuel Morales14, Álvaro Saenz-Cusi15, Delvys Rodríguez16, Virginia Calvo1, Luis de la Cruz-Merino17, Miguel Ángel de la Cruz18, Antonio Rueda19. 1. Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain. 2. Biomedical Sciences Research Institute, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain. 3. National Institute of Epidemiology, Carlos III Institute of Health, Madrid, Spain. 4. La Fe University Hospital, Valencia, Spain. 5. Gregorio Marañón University Hospital, Madrid, Spain. 6. Canary Islands University Hospital, Santa Cruz de Tenerife, Spain. 7. San Joan de Reus University Hospital, Tarragona, Spain. 8. Virgen de la Victoria University Hospital, Málaga, Spain. 9. Valencia General Hospital, Valencia, Spain. 10. Gran Canaria Doctor Negrín University Hospital, Las Palmas de Gran Canaria, Spain. 11. Pontevedra Hospital Complex, Pontevedra, Spain. 12. Oncology Institute of Valencia, Valencia, Spain. 13. General Hospital of Elche, Alicante, Spain. 14. Nuestra Señora de Candelaria University Hospital, Santa Cruz de Tenerife, Spain. 15. Lozano Blesa Clinic, Zaragoza, Spain. 16. Gran Canaria Insular Hospital, Las Palmas de Gran Canaria, Spain. 17. Virgen de la Macarena University Hospital, Seville, Spain. 18. Virgen de la Salud University Hospital, Toledo, Spain. 19. Costa del Sol Hospital, Málaga, Spain.
Abstract
BACKGROUND: Relatively few studies have analyzed the mortality of follicular lymphoma (FL) patients in comparison with a sex- and age-matched general population. This study analyzed the overall survival (OS) of patients with FL and compared their survival with the expected survival of a general population. METHODS: Patients diagnosed with FL were prospectively enrolled from 1980 to 2013. Standardized mortality ratios (SMRs) were obtained from yearly sex- and age-specific mortality rates in Spain, and OS was compared with age- and sex-matched general population data. RESULTS: A total of 1074 patients with newly diagnosed FL were enrolled. The median OS was 231 months (95% confidence interval [CI], 195-267 months). Event-free survival at 12 months (EFS12) and event-free survival at 24 months (EFS24) were associated with an increased probability of early death, with an SMR of 10.27 (95% CI, 8.26-12.77) for EFS12. The overall SMR, including all causes of death, was 2.55 (95% CI, 2.23-2.92), and it was higher for women (SMR, 3.02; 95% CI, 2.48-3.67) and young adults (SMR, 6.01; 95% CI, 3.13-11.55). More than 10 years after the diagnosis, mortality rates for FL patients were lower than those for the general population (SMR, 0.47; 95% CI, 0.28-0.78). When FL was excluded as a cause of death, the overall SMR was 1.35 (95% CI, 1.11-1.65) without a statistically significant mortality increase in the >60-year-old group in comparison with age- and sex-matched general population data. More than 15% of the patients included in the study (n = 158) had more than 10 years of follow-up. CONCLUSIONS: EFS12 and EFS24 predict an early increase in mortality. The long-term SMR, over the course of 10 years of follow-up, shows that patients with FL have a risk of dying similar to that of a sex- and age-matched general population. Cancer 2017;123:3709-3716.
BACKGROUND: Relatively few studies have analyzed the mortality of follicular lymphoma (FL) patients in comparison with a sex- and age-matched general population. This study analyzed the overall survival (OS) of patients with FL and compared their survival with the expected survival of a general population. METHODS:Patients diagnosed with FL were prospectively enrolled from 1980 to 2013. Standardized mortality ratios (SMRs) were obtained from yearly sex- and age-specific mortality rates in Spain, and OS was compared with age- and sex-matched general population data. RESULTS: A total of 1074 patients with newly diagnosed FL were enrolled. The median OS was 231 months (95% confidence interval [CI], 195-267 months). Event-free survival at 12 months (EFS12) and event-free survival at 24 months (EFS24) were associated with an increased probability of early death, with an SMR of 10.27 (95% CI, 8.26-12.77) for EFS12. The overall SMR, including all causes of death, was 2.55 (95% CI, 2.23-2.92), and it was higher for women (SMR, 3.02; 95% CI, 2.48-3.67) and young adults (SMR, 6.01; 95% CI, 3.13-11.55). More than 10 years after the diagnosis, mortality rates for FL patients were lower than those for the general population (SMR, 0.47; 95% CI, 0.28-0.78). When FL was excluded as a cause of death, the overall SMR was 1.35 (95% CI, 1.11-1.65) without a statistically significant mortality increase in the >60-year-old group in comparison with age- and sex-matched general population data. More than 15% of the patients included in the study (n = 158) had more than 10 years of follow-up. CONCLUSIONS: EFS12 and EFS24 predict an early increase in mortality. The long-term SMR, over the course of 10 years of follow-up, shows that patients with FL have a risk of dying similar to that of a sex- and age-matched general population. Cancer 2017;123:3709-3716.
Authors: Clémentine Sarkozy; Matthew J Maurer; Brian K Link; Hervé Ghesquieres; Emmanuelle Nicolas; Carrie A Thompson; Alexandra Traverse-Glehen; Andrew L Feldman; Cristine Allmer; Susan L Slager; Stephen M Ansell; Thomas M Habermann; Emmanuel Bachy; James R Cerhan; Gilles Salles Journal: J Clin Oncol Date: 2018-11-27 Impact factor: 44.544
Authors: Aino Rajamäki; Mika Hujo; Reijo Sund; Roosa E I Prusila; Milla E L Kuusisto; Hanne Kuitunen; Esa Jantunen; Santiago Mercadal; Marc Sorigue; Juan-Manuel Sancho; Kaisa Sunela; Outi Kuittinen Journal: Cancer Date: 2022-04-13 Impact factor: 6.921